

MAR 19 1999



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

#19


Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs (HFY-20)  
Food and Drug Administration  
5600 Fishers Lane, Room 15-22  
Rockville, MD 20857

Dear Mr. Wilson:

The attached application for patent term extension of U.S. Patent No. 5,712,155 was filed on December 22, 1998, under 35 U.S.C. § 156. The patent does not now claim the approved product, its method of use or method of manufacturing, however, Reissue Application No. 09/144,502, filed August 31, 1998 contains claims to the method of manufacturing the active ingredient of ENBREL™. If the reissue application is allowed, the application as reissued may be subject to patent term extension under 35 U.S.C. § 156 based upon the regulatory review period of ENBREL™.

The assistance of your Office is requested in confirming that the product identified in the application, ENBREL™, has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period after the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (703) 306-3159 (telephone) or (703)308-6916 (facsimile).

  
Karin Tyson  
Senior Legal Advisor  
Special Program Law Office  
Office of the Deputy Assistant Commissioner  
for Patent Policy and Projects

cc: Robert Armitage  
Vinson & Elkins LLP  
Suite 700  
1455 Pennsylvania Ave. NW  
Washington D.C. 20004-1008